Cargando…

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approved for use in diabetes and heart failure, but i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Amr, Mekhaeil, Bassem, Biziotis, Olga-Demetra, Tsakiridis, Evangelia E., Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Mesci, Aruz, Liu, Stanley, Berg, Tobias, Bramson, Jonathan L., Steinberg, Gregory R., Tsakiridis, Theodoros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491589/ https://www.ncbi.nlm.nih.gov/pubmed/37684337 http://dx.doi.org/10.1038/s42003-023-05289-w

Ejemplares similares

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
por: Biziotis, Olga‐Demetra, et al.
Publicado: (2023)

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses
por: Tsakiridis, Evangelia E., et al.
Publicado: (2021)

(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
por: Mesci, Aruz, et al.
Publicado: (2023)

Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer
por: Gouran-Savadkoohi, Mohammad, et al.
Publicado: (2023)

Collagen and Calcium Binding EGF Domains 1 (CCBE1) in cancer – a new role past lymphatics?
por: Mesci, Aruz, et al.
Publicado: (2017)

The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
por: Villani, Linda A., et al.
Publicado: (2016)

Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
por: Desjardins, Eric M., et al.
Publicado: (2023)

Expression of the glucose transporters GLUT1, GLUT3, GLUT4 and GLUT12 in human cancer cells
por: Barron, Carly, et al.
Publicado: (2012)

Spurious elevation of Prostate‐specific antigen associated with shingles in a prostate cancer patient undergoing active surveillance
por: Mesci, Aruz, et al.
Publicado: (2018)

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance
por: Ahmadi, Elham, et al.
Publicado: (2023)

Inhibition of human lung cancer cell proliferation and survival by wine
por: Barron, Carly C, et al.
Publicado: (2014)

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
por: Furuhashi, Masato, et al.
Publicado: (2016)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
por: Shiba, Kumiko, et al.
Publicado: (2018)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
por: Spertus, John A., et al.
Publicado: (2022)

SGLT2 Inhibitors—A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling
por: Yagi, Takashi, et al.
Publicado: (2022)

Metformin-induced reductions in tumor growth involves modulation of the gut microbiome()
por: Broadfield, Lindsay A., et al.
Publicado: (2022)

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
por: Jojima, Teruo, et al.
Publicado: (2019)

Current Evidence of the Role of the Myokine Irisin in Cancer
por: Tsiani, Evangelia, et al.
Publicado: (2021)

Exposure to the Widely Used Pyrethroid Pesticide Deltamethrin, Does Not Exacerbate High Fat Diet Induced Obesity or Insulin Resistance in C57BL/6J Mice
por: Tsakiridis, Evangelia Evelyn, et al.
Publicado: (2021)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts
por: Storozhuk, Yaryna, et al.
Publicado: (2012)

Sestrin2 Modulates AMPK Subunit Expression and Its Response to Ionizing Radiation in Breast Cancer Cells
por: Sanli, Toran, et al.
Publicado: (2012)

Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography
por: Tsakiridis, Theodoros, et al.
Publicado: (2020)

AMPK β1 reduces tumor progression and improves survival in p53 null mice
por: Houde, Vanessa P., et al.
Publicado: (2017)

Canagliflozin, an Inhibitor of the Na(+)-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia
por: Shim, Bosung, et al.
Publicado: (2023)

Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis
por: Mesci, Aruz, et al.
Publicado: (2017)

Inhibition of Human Lung Cancer Cell Proliferation and Survival by Post-Exercise Serum Is Associated with the Inhibition of Akt, mTOR, p70 S6K, and Erk1/2
por: Kurgan, Nigel, et al.
Publicado: (2017)

Assessing the bipotency of in vitro-derived neuromesodermal progenitors
por: Tsakiridis, Anestis, et al.
Publicado: (2015)

Initial Development of an Electronic Testis Rigidity Tester
por: Mirilas, Petros, et al.
Publicado: (2011)

Amniotic band syndrome
por: Ioannis, Tsakiridis, et al.
Publicado: (2020)

Elephantiasis in pregnancy
por: Tsakiridis, Ioannis, et al.
Publicado: (2019)

Shaping axial identity during human pluripotent stem cell differentiation to neural crest cells
por: Cooper, Fay, et al.
Publicado: (2022)

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2019)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ehapt5bof4nnviuopt9v0nsqpp